KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Cash Flow (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Net Cash Flow readings, the most recent being $202.0 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow rose 112.26% to $202.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.1 billion, a 264.3% increase, with the full-year FY2025 number at $235.0 million, down 5.24% from a year prior.
  • Net Cash Flow hit $202.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $1.4 billion in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $1.4 billion in Q4 2025 to a low of -$1.6 billion in Q1 2025.
  • Median Net Cash Flow over the past 5 years was $114.0 million (2022), compared with a mean of $109.8 million.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 1686.11% in 2023 and later plummeted 1158.02% in 2025.
  • Teva Pharmaceutical Industries' Net Cash Flow stood at $430.0 million in 2022, then surged by 111.4% to $909.0 million in 2023, then tumbled by 88.67% to $103.0 million in 2024, then soared by 1223.3% to $1.4 billion in 2025, then crashed by 85.18% to $202.0 million in 2026.
  • The last three reported values for Net Cash Flow were $202.0 million (Q1 2026), $1.4 billion (Q4 2025), and $51.0 million (Q3 2025) per Business Quant data.